Figures captions
Figure 1 PRISMA flow diagram of
the review selection process
Figure 2 Forest plot depicting
pooled estimates for the association between mortality and
renin-angiotensin system drugs use
Figure 3 Forest plot depicting
pooled estimates for the association between death/Intensive Care Unit
(as a composite outcome) and renin-angiotensin system drugs use
Figure 4 Forest plot depicting
pooled estimates for the association between severe COVID-19 infection
and renin-angiotensin system drugs use
Figure 5 Forest plot depicting
pooled estimates for the association between hospitalisation and
renin-angiotensin system drugs use
Figure 6 Forest plot depicting
pooled estimates for the association between developing Intensive Care
Unit admission and renin-angiotensin system drugs use
Figure 7 Forest plot depicting
pooled estimates for the association between between risk of acquiring
COVID-19 infection and renin-angiotensin system drugs use
Figure 8 Forest plot depicting
pooled estimate for the association between use of mechanical ventilator
and renin-angiotensin system drugs use
Figure 9 Forest plot depicting
pooled estimates for the association between risk of severe acute
respiratory syndrome (SARS)and renin-angiotensin system drugs use
Figure 10 Forest plot depicting
pooled estimates for the association between severe pneumonia and
renin-angiotensin system drugs use